BAJAJ BROKING
GlaxoSmithKline Pharmaceuticals Ltd. secured an income tax refund of ₹222.23 crore for FY 2022-23. The company reported a 37.8% YoY profit increase to ₹182.3 crore and a 60.1% EBITDA surge, driven by strong brand performance.
GlaxoSmithKline Pharmaceuticals Ltd. (GSK Pharma), a leading player in the global healthcare industry, announced on Tuesday, September 3, that it has received an income tax refund of ₹222.23 crore for the assessment year 2022-23. The refund follows an order issued by the Income Tax Department under Section 143(3), which pertains to scrutiny assessments. The news was shared in a regulatory filing with the stock exchanges.
The announcement of the tax refund comes on the heels of a strong financial performance by GSK Pharma in the first quarter of the fiscal year 2024. The company reported a notable 37.8% year-on-year (YoY) increase in net profit, amounting to ₹182.3 crore. This marks a significant rise from the ₹132.3 crore profit reported in the same quarter of the previous fiscal year.
The company's revenue also showed positive momentum, growing by 7% to ₹814.7 crore, compared to ₹761.7 crore in the corresponding period of the preceding fiscal. This growth was supported by robust sales from key brands, including Calpol, Augmentin, and T-Bact, which continued to gain market share.
At the operating level, GSK Pharma's earnings before interest, tax, depreciation, and amortisation (EBITDA) surged by 60.1%, reaching ₹230.6 crore in the first quarter of the current fiscal year. This is a substantial increase from the ₹144 crore reported in the corresponding quarter of the previous fiscal year. The company's EBITDA margin also improved significantly, standing at 28.3% in the reporting quarter, up from 18.9% in the previous year's corresponding period.
The growth in EBITDA and the expansion of margins highlight the company's operational efficiency and its ability to capitalise on market opportunities.
GSK Pharma's continued success can be attributed to the strong performance of its key brands. Calpol, Augmentin, and T-Bact, among others, contributed to a 10% growth in sales. Additionally, the company's respiratory portfolio, including products like Nucala and Trelegy, achieved an impressive 57% growth, further expanding access to critical treatments for patients.
The receipt of the ₹222.23 crore income tax refund, coupled with the robust financial results for the first quarter of FY 2024, underscores GSK Pharma's strong market position and economic health. The company's focus on expanding its key brands and improving operational efficiency continues to drive its growth trajectory.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Gold Rate Today | 15 January 2025 | Gold Price in India
15 Jan, 2025 | 40 Min. read
Delhi Court Discharges JSW Steel in Corruption Case; HC Clears Monnet Takeover
15 Jan, 2025 | 2 Min. read
IRFC Emerges L1 Bidder to Finance ₹3,167 Crore for Banhardih Coal Block
15 Jan, 2025 | 2 Min. read
Cipla’s Tax Demand Reduced to ₹559.18 Crores After Revision
15 Jan, 2025 | 2 Min. read
Govt Plans 5-6% Hike in Highway Budget for FY26 After FY25 Slump
15 Jan, 2025 | 2 Min. read
Rikhav Securities IPO- Key Objective & Deep Analysis
15 Jan, 2025 | 5 Min. read
HCL Tech expands partnership with Microsoft to transform contact centres
14 Jan, 2025 | 2 Min. read
BEL secures new orders worth Rs 561 crore, boosting FY25 order book
14 Jan, 2025 | 2 Min. read
ITI Ltd secures Rs 64 crore contracts for Wi-Fi and CCTV systems
14 Jan, 2025 | 2 Min. read
JSW Energy secures LoI for 3.6 GW KSK Mahanadi power plant
14 Jan, 2025 | 2 Min. read
Biocon Biologics’ Johor Bahru Facility Receives FDA VAI Classification
13 Jan, 2025 | 2 Min. read
Interarch Secures ₹221 Crore Projects in Semiconductors & Energy Storage
13 Jan, 2025 | 2 Min. read
RBI Launches ULI: Transforming Loan Access
August 27, 2024 | 4 Min. read
Textile Sector in India
September 20, 2024 | 5 Min. read
List of IPOs with DRHPs Filed
November 30, 2023 | 3 Min. read
Aditya Birla Group
September 28, 2023 | 10 Min. read
Bajaj Housing Finance Ltd IPO: Things Smart Investors Need to Know
September 05, 2024 | 4 Min. read
Budget Stock Ideas 2024-2025 | Stocks to Buy Today
July 24, 2024 | 4 Min. read
IPO Eligibility Criteria : Full Details
March 15, 2024 | 6 Min. read
What Is the Lock-In Period in IPOs?
October 18, 2023 | 6 Min. read
Godfrey Phillips Announces 2:1 Bonus Shares
September 16, 2024 | 7 Min. read
Jindal Group- A Comprehensive Analysis
September 27, 2024 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading